Educational Symposium
Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors, CVD, and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in ESKD
November 06, 2025 | 12:45 PM - 01:45 PM
Location: Room TBD2, Hilton Americas-Houston
Session Description
Anemia is a common condition in patients with CKD that reduces quality of life and increases morbidity and mortality risk. Intravenous iron and erythropoiesis-stimulating agents (ESAs) have been the treatment mainstays for CKD-associated anemia. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral medications to treat anemia in patients with ESKD.
CVD is a major component of anemia-related morbidity in ESKD, and through a diverse set of mechanisms, HIF-PHIs may have positive cardiac effects. In patients who become hyporesponsive to ESAs, HIF-PHIs provide an alternative means of treating anemia. This symposium discusses potential cardiovascular effects of HIF-PHIs and summarizes cardiovascular outcomes from clinical trials. Mechanisms of hyporesponsiveness to ESAs are also explored.
Support is provided by an educational grant from Akebia Therapeutics, Inc.
Learning Objective(s)
- Outline the mechanisms by which HIF-PHIs treat anemia in patients with kidney diseases
- Describe the cardiovascular effects of HIF-PHIs
- Explain the mechanisms underlying a poor response to ESAs
Learning Pathway(s)
- Dialysis
- Pharmacology
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Cardiovascular Effects of HIF-PHIs in ESKD
12:55 PM - 01:15 PM
- Are HIF-PHIs the Solution to ESA Hyporesponsiveness in ESKD?
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM